Department of Obstetrics and Gynecology (Gynecology)

Medicine & Life Sciences

1. Endometrial Neoplasms 100%
2. Uterine Cervical Neoplasms 63%
3. Ovarian Neoplasms 61%
4. Japan 56%
5. Neoplasms 43%
6. Uterus 27%
7. Carcinoma 26%
8. Ovarian Epithelial Carcinoma 22%
9. Clear Cell Adenocarcinoma 21%
10. Gynecology 21%
11. Obstetrics 20%
12. Drug Therapy 19%
13. Paclitaxel 18%
14. Carboplatin 18%
15. Transplantation 18%
16. Therapeutics 16%
17. Cervical Intraepithelial Neoplasia 16%
18. Survival 15%
19. Adenocarcinoma 14%
20. Uterine Neoplasms 14%
21. Platinum 13%
22. Macaca 13%
23. Lymph Node Excision 13%
24. Cisplatin 13%
25. Genes 12%
26. Mutation 12%
27. Neoplasm Metastasis 12%
28. Endometrial Hyperplasia 11%
29. Microsatellite Instability 11%
30. DNA Mismatch Repair 11%
31. Trachelectomy 11%
32. Lymph Nodes 11%
33. Cervix Uteri 11%
34. Galactosyltransferases 10%
35. Hereditary Nonpolyposis Colorectal Neoplasms 10%
36. Endometrium 10%
37. Endometriosis 10%
38. Hysterectomy 10%
39. Primates 9%
40. Progression-Free Survival 9%
41. Cell Biology 9%
42. Endometrioid Carcinoma 8%
43. Retrospective Studies 8%
44. Cell Line 8%
45. Hysteroscopy 8%
46. Human papillomavirus 16 8%
47. Guidelines 8%
48. Drug Repositioning 8%
49. Medical Oncology 7%
50. Early Detection of Cancer 7%
51. Pregnancy 7%
52. Adjuvant Chemotherapy 7%
53. Ovary 7%
54. Carcinogenesis 7%
55. Infertility 7%
56. Recurrence 7%
57. Safety 7%
58. Biomarkers 7%
59. liposomal doxorubicin 6%
60. Carcinosarcoma 6%
61. Bevacizumab 6%
62. Annual Reports 6%
63. Pharmaceutical Preparations 6%
64. Tumor Biomarkers 6%
65. MicroRNAs 6%
66. Genome 6%
67. Confidence Intervals 6%
68. Indocyanine Green 6%
69. Irinotecan 6%
70. Proteins 6%
71. Multicenter Studies 6%
72. Chemoradiotherapy 6%
73. Fertility 6%
74. Trophoblasts 6%
75. Narrow Band Imaging 5%
76. Glycolipids 5%
77. dienogest 5%
78. DNA 5%
79. pembrolizumab 5%
80. Fertility Preservation 5%
81. Monoclonal Antibodies 5%
82. Medroxyprogesterone Acetate 5%
83. Salpingo-oophorectomy 5%
84. Antigens 5%
85. Genotype 5%
86. Antibodies 5%
87. Germ-Line Mutation 5%
88. Carbohydrates 5%
89. Squamous Cell Carcinoma 5%
90. Macaca fascicularis 5%
91. CA602 antigen 5%
92. Adenocarcinoma in Situ 5%
93. Assisted Reproductive Techniques 5%
94. Hereditary Breast and Ovarian Cancer Syndrome 5%
95. Immunotherapy 5%
96. Epitopes 5%
97. Squamous Intraepithelial Lesions 5%
98. taxane 5%
99. Docetaxel 5%